Comparing the diagnostic value of targeted with metagenomic next-generation sequencing in immunocompromised patients with lower respiratory tract infection

Table 1 Characteristics of patients and baseline of two groups

Characteristic	All patients	Immunocompetent patients	Immunocompromised patients	P-value
Number, n(%)	88(100.00)	34(38.64)	54(61.36)
Male gender, n (%)	47(53.41)	19(55.88)	28(51.85)	0.247
Age (year), median (Q1, Q3)	64(55, 69)	61(55, 68)	65(56, 69)	0.833
Laboratory findings
WBC (10⁹/L), median (Q1, Q3)	8.29(5.51, 11.16)	7.46 (5.16,9.79)	8.64(6.10, 13.50)	0.965
Monocyte count(10⁹/L), median (Q1, Q3)	0.52(0.35, 0.69)	0.52(0.33, 0.61)	0.52(0.37,0.72)	0.965
Comorbidities, n (%)				0.043
Type 2 diabetes	14(15.91)	5(14.71)	9(16.67)
cardiovascular and cerebrovascular diseases	24(27.27)	12(35.29)	12(22.22)
COPD	7(7.95)	5(14.71)	2(3.70)
Immunocompromised status, n (%)
Hematologic malignancy	4(4.55)	NA	4(7.41)
Solid-organ transplantation	31(35.22)	NA	31(57.41)
Solid tumor receiving chemotherapy	5(5.68)	NA	5(9.26)
Immunosuppressive therapy	25(28.41)	NA	25(46.30)
Prolonged corticosteroid therapy^a	24(27.27)	NA	24(44.44)
Autoimmune disease	4(4.55)	NA	4(7.41)
Antibiotics therapy				0.483
No prior antibiotics	15(17.04)	7(20.59)	8(14.81)
Prior antibiotics	73(82.95)	27(79.41)	46(85.19)
Disease severity				0.075
Septic shock, n (%)	4(4.54)	0(0)	4(7.41)
Invasive mechanical ventilation, n (%)	21(23.86)	6(17.65)	15(27.78)
Outcome				0.965
Death	13(14.77)	5(14.71)	8(14.81)
survival	74(84.09)	28(82.35)	46(85.19)
unknown	1(1.13)	1(2.94)	0(0)

Abbreviations Q1 and Q3, interquartile range; WBC, White blood cell; NA, not available. The difference based on the t-test was calculated. a Defined as > 0.3 mg/kg/d of prednisone-equivalent for ≥ 3 weeks

ISSN: 1476-0711